Synthetic lethality of KDM1A and mTOR inhibitors: A novel combination therapy for endometrial cancer

被引：0
|
作者：
Pitta-Venkata, Prabhakar [1 ]
Palacios, Bridgitte [1 ]
Chen, Yihong [1 ]
Viswanadhapalli, Suryavathi [1 ]
Pratap, Uday P. [1 ]
Luo, Yiliao [1 ]
Li, Mengxing [1 ]
Altwegg, Kristin [1 ]
Li, Xiaonan [1 ]
Suzuki, Takayoshi [2 ]
Tekmal, Rajeshwar Rao [1 ]
Kost, Edward [1 ]
Sareddy, Gangadhara Reddy [1 ]
机构：
[1] UT Hlth San Antonio, San Antonio, TX USA
[2] Kyoto Prefectural Univ Med, Kyoto, Japan
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-280
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
280
引用
收藏
页数：2
相关论文
共 50 条
  • [11] LSD1/KDM1A inhibitors in clinical trials: advances and prospects
    Fang, Yuan
    Liao, Guochao
    Yu, Bin
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (01)
  • [12] Targeting Histone Lysine Demethylase LSD1/KDM1A as a New Avenue for Cancer Therapy
    Fang, Yuan
    Liao, Guochao
    Yu, Bin
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2019, 19 (11) : 889 - 891
  • [13] A novel multi-functional KDM1A chemoprobe as a tool for clinical cancer research.
    Ciceri, Filippo
    Lunardi, Serena
    Mascaro, Cristina
    Rodriguez, Raquel Ruiz
    Carceller, Elena
    Ortega, Alberto
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [14] Polymyxins and quinazolines are LSD1/KDM1A inhibitors with unusual structural features
    Speranzini, Valentina
    Rotili, Dante
    Ciossani, Giuseppe
    Pilotto, Simona
    Marrocco, Biagina
    Forgione, Mariantonietta
    Lucidi, Alessia
    Forneris, Federico
    Mehdipour, Parinaz
    Velankar, Sameer
    Mai, Antonello
    Mattevi, Andrea
    SCIENCE ADVANCES, 2016, 2 (09):
  • [15] Synthetic lethality in personalized cancer therapy
    Ying Pang
    Meng Cheng
    Mu Chen
    Kaijun Zhao
    Yuanyuan Yin
    Min Liu
    Jing Zhang
    Chunlong Zhong
    Genome Instability & Disease, 2023, 4 (2) : 121 - 135
  • [16] Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors
    Lord, Christopher J.
    Tutt, Andrew N. J.
    Ashworth, Alan
    ANNUAL REVIEW OF MEDICINE, VOL 66, 2015, 66 : 455 - 470
  • [17] Combination therapy with mTOR and PI3 kinase inhibitors is broadly synergistic in a wide variety of endometrial cancer cells
    Yang, Shujie
    Xiao, Xue
    Meng, Xiangbing
    Leslie, Kimberly K.
    CANCER RESEARCH, 2011, 71
  • [18] Discovery of Reversible Inhibitors of KDM1A Efficacious in Acute Myeloid Leukemia Models
    Romussi, Alessia
    Cappa, Anna
    Vianello, Paola
    Brambillasca, Silvia
    Cera, Maria Rosaria
    Dal Zuffo, Roberto
    Faga, Giovanni
    Fattori, Raimondo
    Moretti, Loris
    Trifiro, Paolo
    Villa, Manuela
    Vultaggio, Stefania
    Cecatiello, Valentina
    Pasqualato, Sebastiano
    Dondio, Giulio
    So, Chi Wai Eric
    Minucci, Saverio
    Sartori, Luca
    Varasi, Mario
    Mercurio, Ciro
    ACS MEDICINAL CHEMISTRY LETTERS, 2020, 11 (05): : 754 - 759
  • [19] Metabolic synthetic lethality in cancer therapy
    Zecchini, Vincent
    Frezza, Christian
    BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS, 2017, 1858 (08): : 723 - 731
  • [20] A new cancer therapy strategy: Synthetic lethality induced by inhibition of mTOR and cMYC and JNK activation
    Chen, Hui
    Rivera, Jason
    Paradise, Marc
    Xu, Zihan
    Mognol, Giuliana
    Varner, Judith
    CANCER RESEARCH, 2024, 84 (06)
12345